Cullinan Therapeutics, Inc. (CGEM)
CGEMNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$11.82
+0.6058 (+5.40%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $754.88m
- P/E
- –
- EPS, last 4 quarters
- $-3.10
- Dividend yield
- –
- Day range
- –
- 52-week range
- $6.73 to $23.19
- Average volume
- 991.7k
- Previous close
- $11.22
Analysts
11 coveringBuy11 buy, 0 hold, 0 sell
Targets a year out average $35.73, +202.2% from here
Earnings
next estimate $-0.7900Next report
Sep 2025
+18.9%
Dec 2025
+3.8%
Mar 2026
+6.3%
Jun 2026
-14.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$55.59m | -$55.26m | -$53.70m | -$57.25m |
| Net income | -$50.61m | -$50.71m | -$49.66m | -$53.70m |
News
8 latest- Cullinan Therapeutics Announces Velinotamig Clinical Data Presented at ACR Convergence 2026Fintel · 9 hours ago
- Cullinan Reports Phase 1b/2a Study Data For Velinotamig In SLE Patients; Stock Up RTTNews · 19 hours ago
- Cullinan Therapeutics Reports Phase 1 Trial Data for CLN-049 with 19% and 21% CRc Rates in AML and MDS PatientsFintel · 5 days ago
- Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?Zacks · Oct 29, 2026
- 3 Growth Stocks Under $20 With Hard Catalyst Dates AheadMarketBeat · Oct 28, 2026
- Cullinan Moves CLN-049 Into Phase 2 Development For Relapsed/Refractory AML RTTNews · Oct 8, 2026
- Cullinan's Zipalertinib Combination Heads To FDA After Positive Phase 3 Lung Cancer Trial RTTNews · Oct 1, 2026
- Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049MarketBeat · Sep 28, 2026
The company
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/ , and follow Cullinan on LinkedIn and X .
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- cullinantherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.